- Decision Resources: Type 2 diabetes market in China to nearly double by 2014
- Oramed announces publication in diabetes journal
- UnitedHealth: Cost of diabetes could be $3.35 trillion by 2020
- Walgreens' Pegus to discuss impact of diabetes management on healthcare costs
- Decision Resources: More patients switch to Onglyza from Merck's Type 2 diabetes drugs
MANCHESTER, N.H. — Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.
Boston Therapeutics announced that it had filed an application with the Food and Drug Administration for chewable metformin tablets. The drug is a version of Bristol-Myers Squibb's Glucophage.
"Metformin is one of the most widely prescribed diabetes drugs in the world, and our neural chemistry polysaccharide formulation will benefit prediabetic and diabetic patients," Boston Therapeutics CEO David Platt said. "This new option in treatments fits into our pipeline of other diabetes therapeutics, including Ipoxyn for limb ischemia and PAZ-320 for blood glucose management."